This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More
by Zacks Equity Research
The Q4 earnings season is on its last legs as results from 358 S&P 500 members or 71.6% of the index's total membership is already out.
Gilead (GILD) Announces Data on Combination Therapy for HIV
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) recently announced positive data from a phase II study on HIV cocktail therapy.
Lilly's Olumiant Gets Marketing Authorization in Europe
by Zacks Equity Research
Eli Lilly and Company (LLY) along with its partner Incyte Corporation (INCY) announced that the European Commission has granted marketing authorization to once-daily baricitinib in Europe.
Glaxo (GSK) Beats on Q4 Earnings, Posts Dismal '17 View
by Zacks Equity Research
GlaxoSmithKline plc (GSK)'s fourth quarter beat estimates but the outlook for 2017 was weak amid a potential entry of generics for Advair.
Sanofi (SNY) Q4 Earnings In Line; Can Sell Praulent for Now
by Zacks Equity Research
Sanofi (SNY) reported fourth-quarter 2016 earnings of 67 cents per American depositary share, which was in line with the Zacks Consensus Estimate.
Strong Q4 Earnings Ahead of the Bell: TWX, GSK, ALK
by Mark Vickery
A slew of new Q4 earnings reports hit the tape this morning, covering a wide range of industries from pharma to airlines to media.
Glaxo (GSK) Misses Q4 Earnings, Revenues Rise Y/Y
by Zacks Equity Research
Glaxo reported core earnings of 48 cents per American depositary share, missing our consensus estimate of 57 cents.
Amgen's Secondary Hyperparathyroidism Drug Approved in U.S.
by Zacks Equity Research
Amgen Inc. (AMGN) announced that the FDA has approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
GW Pharma (GWPH) Posts Narrower-than-Expected Loss in Q1
by Zacks Equity Research
GW Pharmaceuticals plc (GWPH) reported first-quarter fiscal 2017 loss of 77 cents per share, much narrower than both the Zacks Consensus Estimate of a loss of $1.35 and the year-ago figure of 82 cents.
Drug Stock Q4 Earnings to Watch on Feb 8: AGN, GSK & More
by Zacks Equity Research
How will these four drug stocks, AGN, GSK, ALNY and SNY, which are all scheduled to report Q4 results on Feb 8, fare this earnings season?
Merck???s Keytruda Gets Priority Review for Bladder Cancer
by Zacks Equity Research
Merck & Co., Inc.???s (MRK) two supplemental Biologics License Applications (sBLA) for its anti-PD-1 therapy, Keytruda, have been accepted under priority review by the FDA.
GlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
GlaxoSmithKline plc (GSK) is scheduled to report fourth-quarter 2016 and full-year results on Feb 8. Last quarter, the company delivered a positive earnings surprise of 7.79%.
Merck Keytruda Gets EU Approval for First-Line Lung Cancer
by Zacks Equity Research
Merck & Co., Inc. (MRK) announced that its anti-PD-1 therapy Keytruda has been approved by the European Commission for the first-line treatment of adult patients with metastatic non-small cell lung cancer.
Is GlaxoSmithKline (GSK) a Great Stock for Value Investors?
by Zacks Equity Research
Value investing is easily one of the most popular ways to find great stocks in any market environment.
Merck: Keytruda+Chemo Gets Priority Review for Lung Cancer
by Zacks Equity Research
Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) for its anti-PD-1 therapy, Keytruda, has been accepted under priority review by the FDA.
Bristol-Myers, J&J Ink Immunotherapy Research Collaboration
by Zacks Equity Research
Bristol-Myers (BMY) entered into an immunotherapy clinical research collaboration with Johnson & Johnson to evaluate a combination of Opdivo and Darzalex.
4 Reasons Why Pfizer (PFE) Could be a Great Pick in 2017
by Zacks Equity Research
Pfizer's shares surpassed that of large-cap pharma industry in 2016. The stock rose 0.6% in 2016.
Merck (MRK) Does Well in 2016: Reasons for Outperformance
by Zacks Equity Research
Merck & Co. Inc.'s (MRK) share price is up 12.1%, so far this year.
Merck Keytruda Gets CHMP Nod for First-Line Lung Cancer
by Zacks Equity Research
Merck & Co., Inc. (MRK) announced that its anti-PD-1 therapy, Keytruda, was rendered a positive opinion in the EU for the first-line treatment of metastatic lung cancer.
Pfizer Chantix Label Warning Lifted in U.S.; to Add New Data
by Zacks Equity Research
Pfizer, Inc. (PFE) announced that the FDA has lifted a boxed warning about neuropsychiatric side effects from the label of its smoking cessation drug, Chantix.
Big Pharma Face Off: Is Merck More Attractive than J&J?
by Zacks Equity Research
Johnson & Johnson (JNJ) and Merck & Co. Inc. (MRK) are some of the better-performing large-cap pharma stocks
Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma
by Zacks Equity Research
Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) ??? the second this week ??? for its anti-PD-1 therapy, Keytruda, has been accepted for priority review by the FDA.
The Zacks Analyst Blog Highlights: Chevron, Glaxo, Aflac, Novo Nordisk and MGM Resorts
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chevron, Glaxo, Aflac, Novo Nordisk and MGM Resorts
Is Brexit a Buying Opportunity?
by Tracey Ryniec
Value investors should keep an eye on what is going on in Great Britain right now.
Q2 Earnings Checklist Keeps Rolling Out: BA, CMCSA, GSK & Others
by Mark Vickery
After a busy session after the bell yesterday, including strength from Apple, we see another long list of reporting companies this morning.